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Abstract
Staphylococcus aureus is a commensal bacterium that causes infections such as sepsis, 
endocarditis, and pneumonia. S. aureus can express a variety of virulence factors, includ‐
ing surface proteins. Surface proteins are characterized by presence of a Sec‐dependent 
signal sequence at the amino terminal, and the sorting signal domain. Surface proteins 
are covalently attached to peptidoglycan and they are commonly known as cell wall–
anchored (CWA) proteins. CWA proteins have many functions and participate in the 
pathogenesis of S. aureus. Furthermore, these proteins have been proposed as therapeutic 
targets for the generation of vaccines. In this chapter, different topics related to CWA 
proteins of S. aureus are addressed. The molecular structure of CWA proteins and their 
role as virulence factors of S. aureus are described. Furthermore, the involvement of CWA 
proteins in the processes of adhesion, invasion of host cells and tissues, evasion of the 
immune response, and the formation of biofilm is discussed. In addition, the role of CWA 
proteins in skin infection and the proposal to use them as potential vaccine antigens are 
described. The information contained in this chapter will help the readers to understand 
the biology of CWA proteins and to recognize the importance of surface molecules of S. 
aureus.
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1. Introduction
Staphylococcus aureus has been widely studied due to their ability to cause infections such as 
sepsis, endocarditis, and pneumonia. Therefore, it is relevant to find new therapeutic targets 
against this bacterium; since the treatments with common antibiotics are seldom effective 
due to the acquisition for multidrug resistance, such as methicillin‐resistant S. aureus (MRSA) 
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strains [1, 2]. S. aureus expresses a variety of virulence factors and some of them are found 
in the bacterial surface (surface proteins). The surface proteins of S. aureus are covalently 
attached to the peptidoglycan, and for that reason, they are named as cell wall‐anchored 
(CWA) proteins. Within the genus Staphylococcus, S. aureus has an average of 24 different CWA 
proteins, whereas Staphylococcus epidermidis and Staphylococcus lugdenensis have less CWA 
proteins. Not all strains of S. aureus have the same 24 CWA proteins on their surfaces, there 
are differences according with their genotypes. With regard to the expression of CWA pro‐
teins, it is dependent on the bacterial growth phase and growth conditions; for example, some 
proteins are expressed only under limited iron concentration [3, 4], while others are expressed 
predominantly in the exponential phase [5], or in the stationary phase of bacterial growth [6]. 
The CWA proteins are classified into four families according to a structure‐function analysis 
and to their different motifs. Currently, the CWA proteins have taken great interest due to 
their multiple functions during the pathogenesis of S. aureus.
2. Structure of CWA proteins
All CWA proteins contain a Sec‐dependent signal sequence at the amino terminal and at the 
carboxyl terminal a sorting signal and a hydrophobic domain (wall‐spanning W). The sort‐
ing signal domain contains the characteristic motif for breaking by the sortase LPXTG (Leu‐
Pro‐X‐Thr‐Gly; wherein X represents any amino acid). The hydrophobic domain retains the 
protein in the bacterial membrane during secretion, so that the sortase can join and carry out 
its transpeptidase function. Between the amino and carboxyl terminal domains, there are dif‐
ferent regions or functional domains. Based on its molecular structure and arrangement, the 
CWA proteins of S. aureus have been classified into four families: the MSCRAMM family, the 
NEAT motif family, the three‐helical bundle family, and the G5‐E repeat family (Table 1).
2.1. The MSCRAMM family
The main feature of this family of proteins is its structural similarity and its mechanism for 
binding the ligand. The general structure of these proteins is a domain A at the amino terminal 
and a region R. The A domain is divided into subdomains: NI, N2, and N3, which integrate the 
ligand‐binding domain. The N2 and N3 subdomains form folding structures IgG‐like [7] that 
are important to form the ligand‐binding site. With respect to ligand‐binding mechanism of 
these proteins, they bind to fibrinogen through the mechanism “dock, lock, and latch” (DLLs) 
by N2 and N3 subdomains. The DLL mechanism occurs when the ligand dock to the open 
apo form and conformation changes create a closed form, in which the ligands are locked 
into a place [8]. Clumping factor A (ClfA) and ClfB proteins of S. aureus and serine‐aspartate 
repeat‐containing protein G (SdrG) of S. epidermidis are representative proteins of this family.
The R region of the Sdr‐ and Clf proteins is composed by repeated Ser‐As, known as the SD 
region. However in the fibronectin‐binding protein A (FnBPA) or (FnBPB), the R region con‐
tains repeated fibronectin‐binding, which have the function of mediating ligand binding. The 
SdrC, SdrD, SdrE, and bone sialo‐binding protein (BBP) proteins, which are MSCRAMM of S. 
aureus, have two or more repeated subdomains named as BSDR, ranging from 110 to 113 amino 
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acids and that are located between the region A and the SD region. The repeated BSDR are 
folded separately and form a rigid bar and it is Ca2+ dependent for structural integrity [9, 10].
An atypical MSCRAMM protein is collagen adhesin (Cna). This protein binds to collagen, 
also has a domain A in its N‐terminal and it is divided into three subdomains N1, N2, and 
N3. The Cna differs from the other members MSCRAMMs because its ligand‐binding domain 
(IgG‐folded) is composed of the N1 and N2 subdomains, and not composed of the N2 and N3 
Protein family Structural motifs and domains* Proteins Function during infection
(1) MSCRAMM
Clf‐Sdr
N‐terminal A region (comprises 
subdomains N1, N2, N3); BSDR repeats (in SdrC, SdrD and SdrE); R region 
(known as SD region, contains serine‐
aspartate repeats)
ClfAa Adhesion to fibrinogen; degradation of 
C3b. Immune evasion
ClfB Fibrinogen, keratin and loricrin 
binding. Nasal colonization by adhesion 
to desquamated epithelial cells
SdrC β‐Neurexin binding. Adhesion to 
desquamated nasal epithelial cells
SrdD Adhesion to desquamated nasal 
epithelial cells
FnBp A region (subdomains N1, N2, N3); R 
region (contains fibronectin‐binding 
repeats)
FnBpA Fibrinogen, fibronectin and elastin 
binding. Adhesion to extracellular 
matrix; cell host invasion.
FnBpB Fibronectin‐binding. Adhesion to 
extracellular matrix; cell host invasion




Cna Collagen binding. Adhesion to 
extracellular matrix
(2) NEAT Near iron transporter motif; C‐terminal 
hydrophilic stretch (in IsdA)
IsdA Heme, fibrinogen, fibronectin, 
cytokeratin and loricrin binding. 
Heme capture and iron uptake; nasal 
colonization
IsdBa Heme, hemoglobin and 3β integrins 
binding. Heme capture and iron uptake; 
invasion of non‐phagocytic cells
IsdH Heme, hemoglobin binding. Heme 
capture and iron acquisition; immune 
evasion by C3b degradation
(3) Three helical 
bundle
Tandemly linked triple‐helical bundle 
domains (known as EABCD); 
repeat‐containing Xr region; 
nonrepetitive Xc region
Protein A IgG, IgM and TNRF1 binding. Evasion 
of immunity; increased inflammation 
during pneumonia and skin infection
(4) G5‐E A region; alternating repeats of G5 
and E domains
SasG Adhesion to desquamated epithelial 
cells; formation of biofilm
*All CWA proteins share an N‐terminal signal sequence and a wall‐spanning region and sorting signal at the C‐terminal 
region.
aAntigens as potential vaccines.
Table 1. Structure‐function of CWA proteins.
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subdomains as other MSCRAMMs typical. Furthermore, the space between domain A and 
the cell wall‐spanning W domain consists of a variable number of repeated B
CNA
 domains, 
which are different from BSDR subdomains. Another difference is that the Cna has a different 
ligand‐binding mechanism named as collagen hug.
2.2. NEAT motif family
The main feature of this family is the presence of near iron transporter (NEAT) motifs, which 
recognize and bind to heme or hemoglobin. Proteins iron‐regulated surface (Isd) A, B, and H 
contain NEAT motif (one NEAT motif for IsdA, two NEAT motif for IsdB, and three NEAT 
motif for IsdH) and these proteins are involved in the capture of heme from the hemoglobin. 
Isd is important for the survival of the bacterium into the host, where the iron is limited. 
Besides, Isd is involved actively in the metabolism of heme. Heme binds to Isd, and then 
heme binds to a membrane transporter protein, which transfers heme into the cytoplasm. 
In the cytoplasm, the iron is released from heme by hemoxygenases [4, 11]. The structure of 
the NEAT domain has been elucidated and the molecular mechanism of ligand‐binding was 
determined [12]. Other Isd proteins can bind different ligands to the heme group, as the case 
IsdA that binds to fibrinogen, fibronectin, cytokeratin 10, and loricrin; and IsdB that binds to 
3β integrins.
2.3. Three‐helical bundle family
The main feature of this family is the presence of several single separately‐folded three‐heli‐
cal bundles. Protein A of S. aureus is the common prototype of this family. Protein A has five 
homologous modules in its amino terminal, known as EABCD (each module has a folding 
three ‐helical bundles) which can bind to different ligands; then there is a Xr region composed 
by repeated octapeptides, which are highly variable number, and finally in the constant Xc 
region [13, 14]. Protein A is a multifunctional CWA protein ubiquitous in S. aureus and fre‐
quently it is used to subtype strains, based on the variation of the DNA sequence‐encoding Xr.
Other proteins of S. aureus containing three‐helix bundles are: the binder protein IgG (Sbi) 
with four three‐helix bundles which is not covalently linked to the cell wall [15, 16], and 
the proteins that have a single three‐helix bundle, the staphylococcal complement inhibitor 
(SCIN) and the extracellular fibrinogen binding protein (Efb) [17], which are involved in the 
immune evasion.
2.4. The G5‐E repeat family
The basic structure of this family is G5‐E repeat domain. Each domain G5 has five conserved 
glycine residues, which adopt a folding of β‐triple helix‐β‐like structure. Currently, it is 
unknown whether this domain is involved in the ligand‐binding function. The region E is 
known as the spacer region and is composed of a sequence of 50 amino acid residues [18, 19]. 
The domain G5 and the region E form the structure of this family. The G5‐E unit is repeated 
in a tandem arrangement. In addition, proteins of this family have a domain A in the amino 
terminal. The surface protein G (SasG) of S. aureus and the accumulation‐associated protein 
(Aap) of S. epidermidis are closely homologous and are members of this family; both proteins 
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are involved in biofilm formation. The G5‐E repeated of Aap and SasG are exposed on the 
surface of the bacterium. For both proteins become functional that must be processed; in the 
case of Aap, the domain A of the amino terminal is removed by proteolytic processing and in 
the case of SasG occurs by limited breaking within G5‐E domains [20].
2.5. Other CWA protein families
There are other CWA proteins with different functional domains such as the legume lectin and 
the nucleotidase. These two groups of CWA proteins are classified outside the four families 
mentioned above, because they are not exclusive of S. aureus. CWA proteins with a legume 
lectin domain are represented by the serine‐rich adhesion of platelet SraP [21]. SraP is com‐
posed of a BR region and a short serine‐rich region (SSR1). The BR region is formed of three 
different structural domains: the legume lectin‐like, the β‐grasp fold (β‐GF) and the cadherin‐
like (CHLD). It has been observed that the function of the BR region is to recognize Neu5Ac‐
containing glycoproteins of mammalian cells; such as the salivary glycoprotein gp340 [22]. 
In addition, the SraP is involved in bacterial adhesion and the invasion of mammalian cells. 
On the other hand, the nucleotidase domain has been identified in CWA protein SasH of 
S. aureus. The nucleotidase motif is enzymatically active and contributes to evade the host 
immune response [23, 24]. It has been shown that when S. aureus is phagocytosed, the SasH 
(also named as synthase adenosine, AdsA) dephosphorylates intracellular ATP to adenosine, 
where the adenosine is immunoregulatory because the adenosine inhibits the oxidative burst 
and promotes the survival of S. aureus within neutrophil [25, 26].
3. Posttranslational modifications of CWA proteins
The MSCRAMMs proteins achieve proteolytic posttranslational modification in the domain 
A. Proteases that remove subdomain N1 of MSCRAMMs are located on the bacterial cell sur‐
face. Proteolytic processing is conducted by a staphylococcal protease, called aureolysin, which 
cleaves between the subdomains N1 and N2 of ClfB and ClfA. For FnBPA, there is not a staphy‐
lococcal protease, the responsible of this processing is the thrombin of the host. Removal of N1 of 
ClfB can decrease the length of the protein and cause lack of binding fibrinogen [5]. It is thought 
that the elimination of N1 subdomain reduces the ability of S. aureus to adhere to fibrinogen, 
loricrin, and cytokeratin 10. The biological importance of the elimination of the subdomain N1 
of ClfA and FnBPA is unclear, since experiments suggest no reducing biofilm formation by 
FnBPA; or no decrease in adhesion to fibrinogen by ClfA and FnBPA processed proteolytically 
[27, 28]. However, it has been reported that under certain conditions, FnBPs are degraded by the 
S. aureus V8 protease, reducing the ability of the bacterium to adhere to fibronectin [29].
Another posttranslational modification is the glycosylation of proteins Clf‐Sdr. It has been 
shown that the glycosyltransferases SdgB and SdgA of S. aureus are responsible to modify 
the SD region of the Clf‐Sdr family. This modification involves adding N‐acetylglucosamine 
residues in the region SD protecting it from the degradation by neutrophil serine protease, 
cathepsin G [30]. Thus, the glycosylation of repeated SD is crucial for functional maintenance 
of MSCRAMMs on the surface of S. aureus.
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4. CWA proteins as virulence factors
The generation of mutants is a useful tool to know the function of a gene; however, the study 
of CWA proteins has been complicated because the generation of defective mutants of CWA 
protein had generated, in some cases, unexpected results due to functional redundancy. For 
example, S. aureus expresses some CWA proteins that bind to fibrinogen, and most of the 
strains can produce two proteins with the same function; in consequence, a mutant protein 
could be replaced by a protein with the correct function. Another difficulty that occurs in the 
study of CWA proteins is to obtain mutants in the isolates of clinical relevance, since the stud‐
ies have been conducted with laboratory strains; such as S. aureus Newman and derivatives of 
NCTC8325 strains. Finally, there is the problem of species because some CWA proteins have a 
specific function in mice but in humans have different functions or behavior [31].
Despite the difficulties mentioned above, the role of CWA proteins in virulence has been stud‐
ied. Human population (20%) is permanently colonized by S. aureus in the nasal cavity [32], 
where the bacterium is able to grow exponentially and to express high levels of mRNA encod‐
ing CWA proteins [33]. ClfB [34] and IsdA [35] contribute in the nasal colonization in rodents, 
and ClfB also in humans [36]. ClfB is capable of binding to keratin 10 of mouse and human 
[37]. Keratin 10 is the largest component of squamous cells. ClfB also binds to the loricrin 
protein [38]. Some other CWA proteins (such as SdrC, SdrD, SasG, and SasX) can promote 
adhesion to squamous cells but the ligand or ligands involved are not known [39–42].
4.1. CWA proteins in the invasion of epithelial and endothelial cells
Recently, S. aureus was recognized as an intracellular pathogen and its ability to survive 
inside neutrophils. S. aureus can be taken directly by nonphagocytic cells and host cells; subse‐
quently, it can cause damage to the above mentioned cells by the production of cytotoxins. In 
addition, intracellular bacterium is protected against the attack by the host because S. aureus 
acquires a state of semidormancy known as small colony variants, which yields intrinsic resis‐
tance to antibiotic therapy [43].
In the case of FnBPA and FnBPB proteins, the binding of these proteins to fibronectin facil‐
itates S. aureus internalization [44–46]. Fibronectin is composed of three different types of 
structural modules, called 1, 2, and 3, of which the modules type 1 contain two β sheets 
involved in interactions with the binding domains of FnBPs [47]. In addition, an arginine‐gly‐
cine‐aspartate sequence of one of the modules type 3 of fibronectin is recognized by integrins. 
Particularly, the interactions of fibronectin with FnBPs and integrin α5β1 initiate the activa‐
tion of a signaling cascade that triggers a cytoskeletal rearrangement in the host cell, which 
causes endocytosis of S. aureus [48].
4.2. Immune system and inflammation
The CWA proteins are involved in immune evasion. Protein A binds to the Fc region of IgG, 
this binding leads to an incorrect orientation of IgG antibody, preventing the recognition of 
the bacterium by neutrophils and the activation of the classical complement pathway [49]. 
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Furthermore, it has been demonstrated that in pulmonary epithelial cells, protein A is capable 
of interacting with tumor necrosis factor receptor 1 (TNFR1), triggering the production of 
interleukin‐8 (IL‐8) and the neutrophil recruitment, promoting inflammation and tissue dam‐
age [50]. Also it has been reported the involvement of protein A in the production of inter‐
feron β (IFNβ) and IL‐6 in a mouse pneumonia model [51].
ClfA and Can are involved in evading the immune system by recruiting regulators of comple‐
ment pathway [52]. Furthermore, ClfA is involved in bacterial survival by binding to fibrin‐
ogen, because in a sepsis model this interaction reduces the probability of S. aureus to be 
eliminated by neutrophils [53]. It has also demonstrated the importance of modifying ClfA by 
glycosyltransferases, which add N‐acetylglucosamine to the SD region, thereby preventing 
the proteolysis by cathepsin‐B from human neutrophils [30].
4.3. Biofilms
One of the major virulence factors of S. aureus is its ability to form biofilms on implanted med‐
ical devices, which favors resistance to antibiotics, survival, and dissemination [31]. In the 
formation of biofilms, a polysaccharide matrix is involved, particularly the molecule poly‐N‐
acetylglucosamine (PNAG) or also called adhesin intercellular polysaccharide (PIA), whose 
production depends on the proteins encoded by the operon icaADBC (intracellular adhesion) 
[54, 55]. Furthermore, the CWA proteins of the cell‐wall are also involved in biofilm forma‐
tion, such as Bap, ClfB, FnBPs, SasC, SasG, and protein A [31]. It has been shown that Bap and 
SasC are involved in adhesion of S. aureus to polystyrene surfaces and the bacterial accumula‐
tion in biofilm formation [56, 57]. In the case of FnBPs, it has been proposed that N2 and N3 
subdomains of the domain A are required to promote the bacterial accumulation in biofilm 
formation [27]. The mechanism of biofilm formation involving SasG consists of an array of 
loop structures, which are capable of interacting with other SasG located on the surface of 
another bacterium, thus allowing the accumulation of S. aureus [18].
5. Involvement of CWA proteins in skin infections
The study of the participation of CWA proteins in skin infections and abscess formation 
has been achieved mainly in animal models with CWA protein mutant strains of S. aureus 
(Table 2). S. aureus strains deficient in sortase proteins, which lost all CWA proteins, are 
unable to form abscess in mice [58, 59]. Mice inoculated with S. aureus strain Newman, defi‐
cient in ClfA, showed a lower bacterial load in skin abscesses compared with the wild‐type 
strain [60]. The ClfA protects the bacterium from phagocytosis by neutrophils because ClfA 
recruits fibrinogen to the surface of the bacterium, thereby preventing the opsonization and 
recognition by receptors of phagocytic cells.
In a murine skin abscess model, infected with S. aureus LS‐1 strain, mutant in FnBPA and FnBPB, 
the bacterial load decreased [60]. FnBPs is also able to adhere and invade the skin keratinocytes 
[61], thus contributing to the development of skin infection. SasX contributes to skin infection, 
which was demonstrated in a murine skin infection model in challenge with a SasX‐deficient 
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strain of S. aureus, who produced smaller abscesses compared with those infected with the wild‐
type strain. In mice inoculated subcutaneously with the S. aureus Newman mutant strain, pro‐
tein A‐deficient, the bacterial load on the skin abscesses was significantly lower than abscesses 
infected the wild‐type strain. The role of protein A during skin infection by S. aureus is probably 
by evading the immune response, since protein A binds to IgG and decrements B cells, prolong‐
ing the time of bacterial binding with the ligand of the skin. Protein A leads a proinflammatory 
response in the skin, because the protein A binds to TNFR1 of human keratinocytes and upregu‐
lates the expression of COX‐2 and IL‐8, driving shot downstream of the kinases, which results in 
the activation of NFkB and AP‐1 [62]. IsdA has a function of resistance against the mechanisms 
of human innate immune defense and its presence on the surface of S. aureus causes that the 
bacterium to be more hydrophilic and is negatively charged [63, 64]. In a rabbit skin infection 
model, transcription levels of isdB were increased 24 h post infection [65], suggesting that it may 
have a role during infection of the skin. The Isd proteins bind to the ligands on skin cells, and it 
is probably Isd that is involved in the skin infection.
6. CWA proteins as vaccines
Currently, there is a proposal to use recombinant CWA proteins as potential vaccine antigens. 
In animal models, the use of CWA proteins has induced immunological protection against S. 
aureus through the production of anti‐S. aureus antibody [66–68]. However, it has been docu‐
mented that IsdB vaccine produced immunity in animals, but not in patients with severe infec‐
tions after cardiothoracic surgery (phase III test) [69, 70]. A strategy to increase vaccine efficacy 
is to develop multiple vaccines, a vaccine containing four antigens of CWA proteins resulted 
in greater protection in mouse [68] compared to a single antigen vaccine. Furthermore, the 
stimulation of humoral immunity is insufficient for protection in humans; subsequently adju‐
vants that trigger an immune response mediated by T helper 1 (Th1) and/or T helper 17 (Th17) 
cells, as well as recruit of neutrophils by IL‐17 and IFNγ would be important.
6.1. CWA proteins such as T‐cell antigen
Up to date, the mechanism of immune system activation by CWA proteins is unknown except 
for the protein A that binds to TNFR1 and induces the production of interleukin‐8 (IL‐8) 
Infection model Mutant CWA in S. aureus Result
Murine kidney abscess Sortase No abscess formation in the kidneys
Murine skin infection ClfA Decreased CFU in the skin abscess
Murine skin infection FnBPA and FnBPB Decreased CFU in the skin abscess
Murine skin infection SasX Smaller abscesses in the skin
Mice inoculated subcutaneously Protein A Decreased CFU in the skin abscesses
Rabbit skin infection Wild‐type High transcription level of the isdB 
gene in abscesses
Table 2. CWA protein infection models.
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and the neutrophil recruitment [50]. The anti‐S. aureus vaccines are capable for activating 
the effector T‐cell subsets [71, 72]; however, the epitopes of S. aureus that recognize T‐cells 
are unknown. T‐cells not activated (virgin) increase their cellular proliferation and produc‐
tion of cytokines (phenotype of activated T‐cells) when they are stimulated with extracellular 
proteins of S. aureus, but not when they are stimulated with intracellular proteins of S. aureus 
[73]. Stimulation of virgin T‐cell with membrane proteins from S. aureus produces a high acti‐
vation of T‐cells, the same takes place when they are stimulated with ClfA [74]. ClfA triggers 
immunity antibody‐mediated in a murine model of S. aureus arthritis [67]. On the other hand, 
ClfA nanoparticle applied to the nasal cavity of mice results in a significant protection against 
systemic infection by S. aureus, and an increase cellular immune response Th1 and Th17 [68]. 
Immune cellular response type Th17 has an important function in systemic protection against 
S. aureus, because knockout mice to IL‐17 cytokine are not immunized with ClfA [75]. These 
studies suggest the potential role of ClfA as the major antigen to activate T‐cells.
Currently, ClfA protein is used in multivalent vaccines. Thus, the vaccine designed by Pfizer, 
with the status of Phase II clinical trials, is made with ClfA antigens, capsular polysaccharide 
MNTC, and two proteins (CP5 and CP8) [76, 77]. This vaccine induces a high production 
of antibodies; however, there are no studies on its cellular immunity. NovaDigm I devel‐
oped a vaccine with homologues of ClfA and Als3p [78]; in phase I clinical test, the vaccine 
showed an increase in the production of specific antibody titer and induced Th1 and Th17 cell 
response in humans [77]. ClfA is emerging as a potent stimulator of T‐cells and it is a promis‐
ing antigen vaccine development; however, there is little research on the potential of other 
CWA proteins to activate T‐cells. Therefore, studies to determine which CWA proteins cause 
a high T‐cell response should be performed to identify potential proteins for future vaccines.
7. Conclusions
Although it has recognized the role and ligands for some CWA proteins of S. aureus, there are 
other CWA proteins whose function in humans is unknown. The structural analysis of CWA 
proteins is a powerful tool to determine their role in S. aureus; however, the use of molecular 
techniques and animal models are essential for discovering new ligands and/or functions of 
the CWA proteins, which could be relevant in S. aureus pathogenicity.
On the other hand, the immune response of the CWA protein also requires more studies, since 
the mechanism by which CWA proteins interfere with the host innate immune response is 
unknown, in particular regulation of complement activation. In addition, determining CWA 
proteins causing a cellular immune response is crucial for the generation of new vaccines.
Most studies of CWA proteins have been conducted with laboratory strains. These studies 
should be extended in clinical isolates, where the variation of ligand binding of the CWA pro‐
teins is considerable. Additionally, the regulatory system of the expression of CWA proteins 
is still insufficient, because the expression of CWA proteins depends on the strain understudy.
Surface proteins have a wide range of functions that are essential for colonization and sur‐
vival of S. aureus in the host. Although the structural analysis of the CWA proteins has been 
crucial to define the mechanism of these processes and has provided the classification of the 
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CWA proteins, there are many questions to understand completely the functions of the CWA 
proteins in the pathogenesis of S. aureus.
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